Serum CCL13 levels in patients with systemic sclerosis and controls

British Journal of Dermatology

Volumn 165, Issue 1, 2011, Pages 216-218

  Gambichler, T ^a   Yilmaz, E ^a   Hoxtermann S ^a   Kolios, A ^a   Moritz, R ^a   Bechara, F G ^a   Kreuter, A ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MONOCYTE CHEMOTACTIC PROTEIN 4;

ADULT; ALLERGIC REACTION; ATOPIC DERMATITIS; BLOOD LEVEL; COMPARATIVE STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; LETTER; LICHEN SCLEROSUS ET ATROPHICUS; LUPUS ERYTHEMATOSUS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIASIS; SYSTEMIC SCLEROSIS; URTICARIA;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; MONOCYTE CHEMOATTRACTANT PROTEINS; SCLERODERMA, SYSTEMIC;

EID: 79959748954     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10330.x     Document Type: Letter

References (10)

1. Yanaba K, Yoshizaki A, Muroi E, et al. CCL13 is a promising diagnostic marker for systemic sclerosis. Br J Dermatol 2010; 162: 332-6.
2. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5. (Pubitemid 18073738)
3. Gambichler T, Tigges C, Burkert B, et al. Absolute count of T and B lymphocyte subsets is decreased in systemic sclerosis. Eur J Med Res 2010; 15: 44-6.
4. Schmidt K, Martinez-Gamboa L, Meier S, et al. Bronchoalveolar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients. Arthritis Res Ther 2009; 11: R111.
5. Fineschi S, Goffin L, Rezzonico R, et al. Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of toll-like receptor 4. Arthritis Rheum 2008; 58: 3913-23.
6. Varga J, Abraham D,. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557-67. (Pubitemid 46348510)
7. Yanaba K, Muroi E, Yoshizaki A, et al. Serum CXCL16 concentrations correlate with the extent of skin sclerosis in patients with systemic sclerosis. J Rheumatol 2009; 36: 1917-23.
8. Yanaba K, Yoshizaki A, Muroi E, et al. Serum CCL23 levels are increased in patients with systemic sclerosis. Arch Dermatol Res 2011; 303: 29-34.
9. Homey B, Meller S,. Chemokines and other mediators as therapeutic targets in psoriasis vulgaris. Clin Dermatol 2008; 26: 539-45.
10. Pivarcsi A, Homey B,. Chemokine networks in atopic dermatitis: traffic signals of disease. Curr Allergy Asthma Rep 2005; 5: 284-90. (Pubitemid 41149708)